Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 4Recurrence 2Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Hematologic Diseases 1Disease Progression 1Disease 1Blood Protein Disorders 1

Interventions

Pemetrexed 5ponatinib 4pembrolizumab 4Carboplatin 4Cisplatin 3130-nm albumin-bound paclitaxel 3tetulomab tetraxetan lu-177 2pralsetinib 2osimertinib 2napabucasin 2fludarabine 2ficlatuzumab 2entinostat 2durvalumab 2atezolizumab 2Rituximab 2Paclitaxel 2Lutetium 2Irinotecan 2Immunotherapy 2Imatinib Mesylate 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cyclophosphamide 2Bortezomib 2Bevacizumab 2vorasidenib 1siltuximab 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms by Histologic Type × ricolinostat × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡